Skip to content
Screener

Operating Income at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$137M+108%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$60.15M-61.8%
Viatris logo
ViatrisVTRS
$6.3M-97.3%
AMP
Amphastar PharmaceuticalsAMPH
$39.73M-5.8%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$31.52M-63.2%

Segments

By segment

See full
Reportable Segment-$8.22M+27.7%

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$494.34M+28.9%
Enterprise value$459.23M+20.0%
P/S9.1×+0.5×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000042
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development3,9624,1058,1669,466
Selling, general and administrative14,06312,70525,04031,777
Total costs and expenses22,04221,37140,69249,456
Loss from operations(8,223)(11,368)(12,427)(30,733)
Other income/(expenses):
Loss on extinguishment of debt(11,683)(11,683)
Interest expense(2,807)(2,781)(5,710)(5,563)
Interest expense related to royalty obligations(972)(1,434)(1,945)(2,871)

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s operating income?
Aquestive Therapeutics, Inc. (AQST) reported operating income of -$8.22M in Q2 2026.
How has Aquestive Therapeutics, Inc.'s operating income changed year-over-year?
Aquestive Therapeutics, Inc.'s operating income increased by 27.7% year-over-year, from -$11.37M to -$8.22M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s operating income?
Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s operating income has grown at a 19.6% compound annual growth rate (CAGR), from -$34.68M to -$71.05M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Aquestive Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude